Hemispherx BioPharma (NYSEAMERICAN:HEB) Stock Price Passes Above 200 Day Moving Average – Should You Sell?

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.70 and traded as high as $9.00. Hemispherx BioPharma shares last traded at $6.70, with a volume of 7,639 shares trading hands.

Hemispherx BioPharma Price Performance

The company’s fifty day simple moving average is $6.70 and its 200 day simple moving average is $6.70.

About Hemispherx BioPharma

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) is a U.S.-based biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of viral infections, cancers and immune system disorders. The company’s research centers on harnessing the body’s innate immune response to address diseases that currently lack broadly effective treatments.

Hemispherx’s principal commercial product is Alferon N Injection, an antiviral drug indicated for the treatment of external genital warts.